• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-30

  A 2026 MedComm study defines NAT1 as a metabolic–immune regulator that restrains ENO1 activity, lactate production, and TRAF6-dependent PD-L1 stabilization in colorectal cancer. Its integrated database, multi-omics, patient, cellular, and mouse-model evidence provides a mechanistic framework for understanding how glycolytic metabolism may influence immune-checkpoint response, while also clarifying the limits of translating LDHA-focused experiments into colorectal cancer immunotherapy research.

• Dibutyryl-cAMP, sodium salt for Signaling Studies

  2026-09-30

  Dibutyryl-cAMP, sodium salt provides a practical way to elevate intracellular cAMP while testing PKA-linked responses in cells and brain-relevant models. This workflow-focused guide covers dose design, organotypic slice experiments, neuronal applications, inflammation studies, and troubleshooting for reproducible pathway interpretation.

• Annexin V-HF647/PI Apoptosis Kit in ESCC

  2026-09-29

  The Annexin V-HF647/PI Apoptosis Kit enables a practical, single-cell view of apoptosis during HOXC9 and AKT/mTOR studies in esophageal squamous cell carcinoma. This guide explains assay biology, experimental design, controls, interpretation, and the limits of linking Annexin V/PI results to mitochondrial mechanisms.

• Pemetrexed Workflows for Folate-Pathway Studies

  2026-09-29

  Use Pemetrexed as more than a cytotoxic readout: it is a practical perturbation tool for mapping folate metabolism, nucleotide stress, and DNA-repair vulnerabilities. This workflow-focused guide connects dose-response design with malignant mesothelioma models and translational assay interpretation.

• MLN2238: From β5 Inhibition to Translational Insight

  2026-09-28

  MLN2238 offers a mechanistically defined route into proteasome stress biology, linking β5-centered proteolytic control with apoptosis, resistance research, and ROS–JNK–CREB adaptation. This article translates those insights into a practical framework for oncology and proteostasis researchers.

• Epilepsy-Associated Cardiac Biomarkers in Baboons

  2026-09-28

  A retrospective study in a captive baboon pedigree found prolonged QT and Fridericia-corrected QT intervals in epileptic animals, alongside a non-significant tendency toward lower heart rate variability. The findings support further study of cardiac measures in epilepsy, but do not establish inherited risk or predict sudden unexpected death in epilepsy.

• Escitalopram in Serotonergic Assay Design

  2026-09-27

  Use Escitalopram as a potency-characterized probe to measure serotonin-transporter function, then connect those mechanistic readouts to the limits of clinical evidence in anxious depression. This workflow emphasizes vehicle control, concentration-response design, and careful interpretation—not assumptions that a cell assay predicts clinical benefit.

• IR-1061 for Deep-Tissue NIR Imaging Workflows

  2026-09-26

  IR-1061 is a near infrared fluorescent dye for OTN-NIR research, but its performance depends on how it is formulated—not simply on the amount of dye added. This workflow-focused guide translates polymer-encapsulation findings into practical loading, control, and troubleshooting choices for deep-tissue imaging studies.

• Pemetrexed in Mesothelioma: Reading DNA Repair Context

  2026-09-25

  Pemetrexed is more than a cytotoxic benchmark: its effects can be interpreted alongside tumor DNA-repair state. This article explains how to separate antifolate response from homologous-recombination vulnerability when designing malignant mesothelioma research.

• Chloroquine: From Lysosomal Mechanism to Translation

  2026-09-25

  Chloroquine is a powerful research probe—but its lysosomal effects, broad immune activity, and uneven translation across models demand careful experimental interpretation.

• Tetrahydromagnolol in CB2 Signaling Workflows

  2026-09-24

  Use Tetrahydromagnolol to probe CB2-linked signaling and test carefully framed hypotheses about inflammation or cell motility. Its reported CB2 potency and GPR55 antagonism support dose-aware workflows—but do not establish a role in the TBXA2R–ERM pathway.

• ABT-263 (Navitoclax): Mechanism and Research Use

  2026-09-24

  ABT-263 (Navitoclax) inhibits anti-apoptotic Bcl-2 family proteins and is used to investigate mitochondrial apoptosis in cancer models. Its value in an apoptosis assay depends on the model’s apoptotic priming and survival-protein profile, so results should not be inferred from target expression alone.

• ARCA Cy5 EGFP mRNA (5-moUTP): Assay Guide

  2026-09-23

  Track labeled mRNA and its translated EGFP product in the same experiment to distinguish delivery from expression. This practical guide shows how to use the reporter to optimize cell-based delivery assays—and where conclusions should stop before moving to disease models.

• Laminin (925-933): A Mechanism-First Assay Guide

  2026-09-23

  Laminin (925-933) is a defined Laminin B1 chain peptide for dissecting receptor-dependent adhesion and chemotaxis. This guide connects its ECM biology with lessons from tau research to improve assay controls, interpretation, and translational relevance.

• Disulfiram Workflows for Proteasome and Pyroptosis

  2026-09-22

  Disulfiram supports two complementary research workflows: copper-associated proteasome inhibition in cancer models and covalent modulation of GSDMD-linked pyroptosis. This guide translates those mechanisms into practical assay design, dosing, controls, and troubleshooting strategies.

8066 records 1/538 page Next 12345 下5页 Last page